Angelini Pharma Hellas is a medium size company located in the northern suburbs of Athens, Greece.
Angelini Pharma Hellas distributes prescription and OTC drugs in order to meet the daily needs of the Greek family with safe and effective products.
Angelini Pharma Hellas markets in Greece international brands like Prixina (Antibiotic), Trittico (CNS) and Tantum (sore throat treatment) that come from Angelini R&D.
Through the years, Angelini Pharma Hellas has developed strong partnerships with leading pharmaceutical companies (AlfaWassermann, Tillotts Pharma AG, Fidia Farmaceutici S.p.A., IBSA Institut Biochimique, TRB Chemedica), which have entrusted Angelini the distribution of their products in the Greek market.
The main therapeutic areas of Angelini Pharma Hellas are: cardiovascular, pain, musculoskeletal, gastroenterology, antibiotics, gynecology, immunology, dermatology and sore throat treatment.
The main brands are: Prixina, Verboril, Hyalart, Asacol, Utrogestan, Altermon/Merional and Tantum.
Angelini Pharma Hellas employs 100 people (75 sales representatives) and holds the 33rd position (values) in the Greek pharmaceutical market with an annual turnover of about 20 M€ (2015).
Contact
Having joined the company at the onset of its presence in the Greek market, Angelini Pharma Hellas’s General Manager, Panagiotis Giannouleas, speaks about the success of the company’s transitional period,…
2023 was a tumultuous year for the pharma industry, with much wailing and gnashing of teeth from executives over the Inflation Reduction Act in the US as well as updated…
After 15 years of economic struggles coupled with political swings to the left and right, Greece seems to be on its surest footing in decades. Indeed, the Economist observed that…
Angelini Pharma’s Gabriele Jannis draws on his experience in both Russia and Romania to highlight some of the key challenges for European mid-caps like Angelini in Greece, the importance of…
After former CEO Pierluigi Antonelli abruptly announced his departure last month, the Italian mid-cap has signed on former Gilead leader, Jacopo Andreose, as its new chief executive. [I am]…
Angelini Pharma CEO Pierluigi Antonelli has announced that he is leaving his position with immediate effect, posing the question of what comes next for the leading Italian mid-cap. Antonelli,…
Seasoned executive Pierluigi Antonelli went from a career in big pharma to Angelini Pharma, a midsized Italian company that has been undergoing major transformation. He shares the motivation behind the…
Speaking exclusively to PharmaBoardroom, Pierluigi Antonelli outlines Angelini Pharma’s progress in transforming from a traditional, Italy-focused, and family-owned firm into a true European innovator. Antonelli outlines the potential impact of…
The latest news from the Italian healthcare and life sciences industries, including the final piece in Angelini’s updated leadership team; the country’s digital health investment timetable; and the details of…
The latest Italy Pharma News, including the government’s decision to make COVID-19 vaccines mandatory for all healthcare workers, the manufacturing of Sputnik V, and recent updates from the country’s top…
Michał Mieszkowski, general manager of Angelini Poland, discusses the strategic significance of Poland for the company, as the third largest affiliate within the global company, the company’s impressive product portfolio…
Peter Wimmer, country manager of Angelini Austria and Germany, discusses the tailored long-term strategy that this exciting Italian pharmaceutical company is implementing to establish a boutique portfolio and the importance…
Dr. Atanas Atanasov, country manager at Angelini Bulgaria, explains the affiliate’s growth to become a top ten player in the Bulgarian industry and highlights the leadership position of its portfolio…
See our Cookie Privacy Policy Here
